

#### Shalby/SE/2023-24/76

October 28, 2023

The Listing Department

National Stock Exchange of India Ltd

Mumbai 400 051.

Corporate Service Department **BSE Limited** Mumbai 400 001.

**Scrip Code: SHALBY** 

**Scrip Code: 540797** 

Through: <a href="https://neaps.nseindia.com/NEWLISTINGCORP/">https://neaps.nseindia.com/NEWLISTINGCORP/</a>

Through: http://listing.bseindia.com

Sub: Investor Presentation for the Quarter and Half Year ended 30th September 2023

#### Dear Sir / Madam,

We are submitting herewith Investor Presentation on financial & operational performance of the Company for the quarter and half year ended September 30, 2023, which will be discussed at the Investor Conference call scheduled on Monday, October 30, 2023.

The said Investor Presentation is being uploaded on website of our Company at <a href="https://www.shalby.org/investors/">https://www.shalby.org/investors/</a> → Investors Presentation.

You are requested to take the same on your record.

Thanking you,

Yours sincerely For **Shalby Limited** 

Tushar Shah
AVP & Company Secretary

Mem. No: FCS-7216

Encl.: as above

**SHALBY LIMITED** 

**Regd. Office:** Opp. Karnavati Club, S. G. Road, Ahmedabad - 380 015, Gujarat, India. Tel: 079 40203000 | Fax: 079 40203109 | info.sg@shalby.org | www.shalby.org CIN: L85110GJ2004PLC044667








Q2 & H1 FY2024







### **AGENDA**



## **Financials Snapshot Q2 FY24**



# Consolidated Financial Highlights

- > Consolidated Revenue at Rs 2,434 mn in Q2 FY24 grew by 17.5% YoY and 1.4% QoQ
- Consolidated EBITDA at Rs.581 mn in Q2 FY24 grew by 37.1%% YoY and 21.9% QoQ
- Consolidated PBT at Rs.426mn in Q2 FY24 grew by 48.6% YoY and 29.3% QoQ
- Consolidated PAT at Rs.276 mn in Q2 FY24 grew by 49.8% YoY and 32.5% QoQ
- > Consolidated Net cash (minus total debt) stood at Rs.705 mn as on Sep'23 v/s Rs.806 mn as on June'23
- > Consolidated Annualized ROCE for Q2 FY24 stood at 20.9% v/s 16.6% in Q1 FY24


# Standalone Financial Highlights

- Standalone Revenue at Rs 2,230 mn in Q2 FY24 grew by 22.0% YoY and 3.1% QoQ
- > Standalone EBITDA at Rs.575 mn in Q2 FY24 grew by 31.6%% YoY and 15.6% QoQ
- Standalone PBT at Rs.473 mn in Q2 FY24 grew by 41.1% YoY and 18.3% QoQ
- Standalone PAT at Rs.304 mn in Q2 FY24 grew by 39.4% YoY and 16.1% QoQ
- > Standalone Net cash (minus total debt) stood at Rs.1,628 mn as on Sep'23 v/s Rs.1,784 mn as on June'23
- Consolidated Annualized ROCE for Q2 FY24 stood at 23.0% v/s 20.0% in Q1 FY24


## **Consolidated Performance Highlights – Q2 FY24**




### **Revenue (INR MN)**




### **PBT & Margin (INR MN)**



### **EBITDA<sup>1</sup> & Margin (INR MN)**



### **ROCE (%)**




1. EBITDA includes other income


## **Consolidated Performance Highlights – H1 FY24**




### Revenue (INR MN)




### PBT & Margin (INR MN)



### **EBITDA<sup>1</sup> and Margin (INR MN)**



### PAT & Margin (INR MN)



1. EBITDA includes other income

## Consolidated P/L & B/S - Q2 FY24



Profit & Loss (NR Mn)					
Particulars (Rs. Millions)	Q2 FY24	Q1 FY24	Q2 FY23	Y-o-Y Growth	Q-o-Q Growth
Revenue	2,434	2,400	2,071	17.5%	1.4%
EBITDA	581	477	424	37.1%	21.9%
EBITDA Margin %	23.9%	19.9%	20.5%		
РВТ	426	330	287	48.6%	29.3%
PBT Margin %	17.5%	13.7%	13.9%		
PAT	276	208	184	49.8%	32.5%
PAT Margins %	11.3%	8.7%	8.9%		

Balance Sheet (INR Mn)		
Gross Borrowings	1,245	
Cash & Cash Equivalents	1,950	
Net Cash/(Debt)	705	
ROCE <sup>1</sup>	20.9%	
Debt/Equity	0.13x	

### **Healthcare Conglomerate**

### **Building An Integrated Orthopedic Solutions Ecosystem**

### **Multi-Specialty**

9 Hospitals across western and central India

- Headroom to grow further with existing bed capacity without major capex
- Ongoing diversification of Arthroplasty with Cardiac, Onco & Neuro-Science, Critical Care, **General Medicine and Transplants**
- · Continue to maintain leadership in Joint Replacement by volume
- Homecare and International business further accelerate growth
- Adopting and Leveraging Technology to bring better medical outcomes and patient reach

### **Franchise**

6 Hospital network


- An Asset light franchise model will leverage Shalby expertise
- Shalby to monitor and control the quality of the services through FOSO and FOSM business model
- These centers to be equipped with the latest high-definition arthroscopic systems and establish state-of-the-art joint replacements facility
- Plans to open 40 SOCE across India

### **Implant**

**USA** based Knee & Hip Manufacturing facility

- Manufacturing US FDA approved implants to sell across the US and international markets
- Highly experienced management team appointed to lead implant business
- Enables Shalby to procure high quality implants for its own consumption in India
- Plans to become USD 100 mn business













## A Legend and Visionary Doctorpreneur behind Shalby





Dr Vikram I Shah, Founder & Chairman

**Dr Vikram I. Shah**, the Founder of Shalby Ltd, is a world-renowned Joint Replacement Surgeon who innovated "**Zero Technique**" that revolutionized Joint Replacement Surgery.

A visionary entrepreneur, he transformed Shalby from a 6 bedded hospital in 1994 to an integrated healthcare group with 15 hospitals network and 2000+ beds across 12 cities in India with an implant manufacturing facility in California, USA and distribution facility in India and South-East Asian countries.

Shalby is today the Biggest Corporate Hospital Group in Western and Central India focusing on all major disciplines in medicine with credentials of being the Largest Joint Replacement Centre of the World, having done over 1,50,000+ successful joint replacement surgeries till date.

Leveraging this expertise, he has envisioned establishing 50 Orthopedic franchises in 30 cities in India.

Shalby Limited is listed on both the premier stock exchanges in India and has the aspiration of growing multifold while preserving the core values of "Passion, Compassion and Innovation".





## **STANDALONE PERFORMANCE (Hospital Business)**

## **Hospital Business Highlights Q2 FY24**



### Global leader in Joint replacements with more than 1,50,000 surgeries and other core surgeries grew by higher double digits

### **Surgery Count and YoY Growth**



**Arthroplasty** 

3,790+ 18%



Nephro & Urology

740+



Oncology

480+





**General & Cosmetics** 

760+



10%

**Orthopedic** 



**740+ 1**3%




**Other Surgery** 

1,080+ 17%

#### **Operational Performance** Q2 Q1 Q2 YoY QoQ **Particulars FY24 FY24 FY23** Growth Growth In-Patient1 (Nos.) 22,652 20,661 18,632 21.6% 9.6% Out Patient<sup>2</sup> (Nos.) 1,26,407 1,19,310 1,15,673 9.3% 5.9% **Surgeries Count** 14.2% 7,771 8,183 6,806 (5%) ARPOB3 (In Rs.) 36,136 37,984 33,409 8.1% (5%) Operational Beds<sup>4</sup> (Nos.) 1,260 1,260 1,235 2.0% 0% Occupied Beds 678 13.1% 626 600 8.4% Occupancy Rate 54% 50% 49% **529 bps** 417 bps ALOS (without Daycare) 3.92 3.97 3.90 0.6% (1.2%)

## **Standalone Business Highlights - Q2 FY24**






## **Standalone Performance Highlights – H1 FY24**




12


### Revenue (INR MN)




### **PBT & Margin (INR MN)**



### **EBITDA<sup>1</sup> and Margin (INR MN)**



### PAT & Margin (INR MN)



1. EBITDA includes other income


## Standalone P&L and B/S - Q2 FY24



### Profit & Loss (Rs. Mn)

Particulars (Rs Mn)	Q2 FY24	Q1 FY24	Q2 FY23	YoY Growth	QoQ Growth
Total Revenue	2,230	2,163	1,828	22.0%	3.1%
EBITDA	575	497	437	31.6%	15.6%
EBITDA Margin %	25.8%	23.0%	23.9%		
PBT	473	400	335	41.4%	18.3%
PBT Margin %	21.2%	18.5%	18.3%		
PAT	304	262	218	39.4%	16.1%
PAT Margin %	13.6%	12.1%	11.9%		

### **Total Revenue to EBITDA**



## Balance Sheet as on Sep'23 (Rs Mn)

Gross Borrowings	201		
Cash & Cash Equivalents	1,829		
Net Cash/(Debt)	1,628		
ROCE <sup>1</sup> (annualised)	23%		


Notos:

## **Hospital Business Highlights**



### **Specialty Revenue Mix**


### **Q2 FY2023**




Medicine,

10%

### Q1 FY2024



### Q2 FY2024



Notes:


Science,

10%

14

## **Hospital Business Highlights**







## **Standalone Business CAGR Growth**



### Shalby Continued to deliver high double-digit growth over the last 2 decades





## **Homecare Business Highlights Q2 FY 2024**



### **Q2 FY2024 Highlights**



Patients Served 15,565 in H1 FY24 v/s 12,686 patients in H1 FY23, grew by 23% YoY




Revenue booked Rs.73 mn during H1 FY24 v/s Rs.44 mn during H1 FY23, grew by 66% YoY




Physio, Diagnostics and Pharmacy are the major revenue contributor in Q2 FY24

### **Industry Catalyst**

- Provide Quality Services through high-end digital systems
- Less Chances of hospital acquired Infection
- Insurance Policies covering Home Healthcare Expenses
- Economical Homecare Services compared to Hospitals





### **Shalby Homecare Comprehensive Services**

## Clinical Update And Research Across Units during Q2 FY24



- 1.2 Kg uterus along with fibroids was removed by virginal morcellation in Shalby Jaipur.
- Left ovarian cystectomy (of approximately 35cm with 10.5kg weight) plus right oophorectomy was performed successfully in Shalby Jaipur.
- A young patient with Ankylosing Spondylitis (challenges with neck fixation, inclination angle of 40 degrees and stiff muscles) were treated with dual mobility OR30 implants to fix hip and spine issues.
- TAVI was performed successfully in a 65-year-old patient suffering with aortic stenosis form past 4 years.
- A pre-mature baby of 27 weeks with birth weight of 800gms was saved with LISA technique (Less invasive surfactant administration).
- Revision surgery is performed in a patient suffering from Segmental Mandibulectomy with PMMC flap reconstruction.
- First pediatric cardiac surgery cases performed for 3-years old child in Shalby Jaipur
- 51 years old gentleman from Yemen presented with history of vague upper abdominal discomfort and post diagnosis found with large fatty component measures 23.1\*24.2\*28.4 cm in retroperitoneal region at upper and mid abdomen predominantly on left side, was successfully removed through a critical surgery.
- 27 Transplants (15 Kidney and 9 Liver) during H1 FY24 and with this we have performed 275+ Transplants so far at our SG and Indore units
- ~20 clinical trials are currently underway across all hospital units and 4 clinical trials are closed during Q2 FY24

## **Key Focus Areas For Future In Hospital business**

24x7 Homecare Services

6

5

Leveraging Technology



#### Global Leader in Joint Replacement with diversification in other specialties

· Continue to maintain global leadership in joint replacements

**Leadership position** 

in Arthroplasty

**Shalby** 

Hospital

• Ongoing diversification with Cardiac Science, Oncology, Neuro-science, Critical Care, **General Medicine and Transplants** 

#### **Prudent Capital Allocation**

· Sustainable Capex business model whereby becoming a preferred O&M partner on revenue sharing mode

 Focus to doubling ROCE in coming year due to operational leverage

#### **Growth in Occupancy Rate**

• Additional 40% of the total bed capacity is available to support organic growth trajectory with limited capex

#### 24x7 Homecare Services

- Provide Quality Services Through High-end digital systems
- Growing no of services and markets outside home locations

## Training and **Training and Development** 3

2

 Investment in high impact training programs will establish a dedicated professional medical base

### **Leveraging Technology**

· Adoption and leveraging technology to provide better medical outcomes, patient reach and satisfaction

### **Expansion Plan**

• Nashik and Mumbai hospitals within development budget and provide access to important local markets





## **FRANCHISE BUSINESS**



## Leveraging Expertise Through Franchise Asset Light Model



Franchise model will leverage Shalby expertise and enable to penetrate faster across pan-India

#### **Business models**

### Franchise Owned – Shalby Operated (FOSO)

- The franchise is responsible for setting up the centre and SHALBY will be responsible for running the day-to-day operations.
- Investments for operational expenses and New medical Equipment by Shalby

### Franchise Owned – Shalby Managed (FOSM)

- Franchisee sets up SOCE Centre. The Operations are managed with a Shalby Appointed Unit Manager
- Centre operated as per Shalby SOP wrt clinical / non-clinical / admin / Purchase / SCM
- 3. Investment for all Operational Expenses / New medical equipments by Franchisee.

#### **SOCE Performance in Q2 FY24**

- Total Surgeries performed at SOCE units (operated and managed) have increased by 116% yoy and 31% qoq
- Total Revenue from operated and managed units has increased by 104% yoy and 27% qoq







Successfully inaugurated SOCE Franchise unit at Ranchi under FOSM model

Upcoming Centre	Bed capacity	Business Model
Rajkot (MOU Signed)	25	FOSO





## SHALBY ACADEMY



## **Shalby Academy**


### **Q2 FY24 highlights**

- More than 610+ students registered in Q2 FY24 in various disciplines like Physiotherapy, Nursing, Lab Technician Nutrition & dietetics, Clinical, Paramedics, Hospital Management, and Pharmacy as part of their academic outreach & upgrade their skills.
- 2. Provided internship to more than **500** physiotherapist
- **3. 115** + Students have been registered for various Paramedic courses like Lab Technicians, OT Technicians, MRI, CT, and XRAY, etc.
- 4. Successfully launched the first batch of BBA with 22 students in hospital management with Sardar Global University.



### **Students Enrolled (In Nos)**





- 30+ Healthcare related courses
- Dedicated Simulation Lab
- In-house Clinical Experts
- Equipped with digital LMS
- In association with various healthcare Institutes

## **Domestic and International Partnership**

























## **IMPLANT BUSINESS**











## Diversified into Knee and Hip Implant Manufacturing In California, USA



### **Backward integration in Orthopedics with Inhouse capacity to consume in India**

80,000+ Components Manufacturing capacity

Vertically integrated Inhouse manufacturing Facility

High Quality US FDA Approved Implants

Made in USA

~30 Years of Zero Product Recalls

Surgeon's Training and Education Program

Seasoned Leadership team with decades of experience in Orthopedics

New Products launches in H2 FY24 and H1 FY25 Presence in USA, Japan, India, and Indonesia

## **Implant Business Performance Q2 FY24**



Total Revenue

Rs. 147 mn


**EBITDA** 

Rs. 2.3 mn


Constructs Sold

2,170+


## **Geographical Sales Mix**



### **USA Customer Sales Mix**




### **Product Sales Mix**



## **Implant Business Roadmap**



### Shalby Advanced Technologies plans to become a Global player in a phased manner







## **ABOUT SHALBY**

## **Shalby At A Glance**






## 29 Years of ELITE Legacy





## **Our Journey & Expansion Plan**






**Expansion Plan:** Mumbai 175 beds, Nashik 146 Beds and Rajkot 25 bed SOCE (FOSO)

## **Hospitals Portfolio**



## **Multispecialty Units (Owned and Operate)**




















## **Franchise Hospital Portfolio**



## **Shalby Orthopedics Centre of Excellence**



(Shalby Operated)



(Shalby Managed)



(Shalby Operated)



(Shalby Managed)

## **Multispecialty**




(Shalby Managed)




(Shalby Managed)

## **Biggest Healthcare Corporate Group in Western and Central India**







## **Sustainability Initiatives**





"We at Shalby are embracing sustainability to drive new values to our business"



Community Connect

240+ Healthcare Camps

15000+ Life impacted



90+ Healthcare Talks

5100+ participation



120+ Healthcare awareness videos

**45+** long and short videos as part of YouTube partnership project so far



10,190+ and 2,440+ Man Hours

Clinical and Non-Clinical training





Male- 57%

Female-43%

Workplace Wellness

Workforce Training

**Healthcare Awareness Programs** 

## **Experienced Board Of Directors**





Dr. Vikram Shah Chairman and Managing Director

Dr. Vikram Shah, serving as Director of the Department of Knee Replacement at Shalby Hospitals since 1993 has nearly three decades of vast professional healthcare experience across the UK, USA and India. In recognition of his outstanding contribution in the field of orthopedics for completion of 1,00,000 joint replacement surgeries, he was conferred with the 'Times Man of the Year' Award by Times of India Group in 2018.



Dr. Ashok Bhatia Independent Director

Dr. Ashok Bhatia, a senior pharma professional has over 40 of professional experience in India and Emerging Markets. In the past, he was President, Emerging Markets with Cadila Healthcare. Currently, he works as an external consultant of McKinsey & Co and is a visiting faculty member at IIM Ahmedabad, IIM Rohtak and IIT Gandhinagar.



Mr. Tej Malhotra Independent Director

Mr. Malhotra boasts four decades of international and Indian industry experience. Past roles include Senior Executive Director at GHCL, Technical Director in a Saudi Calcium Chloride Company, and Executive Engineer at Hindustan Copper. He's a recipient of prestigious awards, including the 'Bhartiya Udyog Ratan' and 'Bhartiya Gaurav' from esteemed organizations, alongside the 'Darbari Seth Award 2009' from the Alkali Manufacturers of India for outstanding soda-ash plant management.



Ms. Sujana Shah Independent Director

Mrs. Sujana Shah, a practicing Chartered Accountant has vast experience of nearly two decades across the domain of finance, accounts, audit, direct and indirect taxes, banking and treasury. Currently, she serves as a partner of V. R. Shah & Associates, Chartered Accountants. She has also audited many reputed public banks in India as Statutory and Internal Auditor.



Mr. Sushobhan
Dasgupta
Non – Executive
Director

Mr. Sushobhan Dasgupta, a healthcare strategist with over 30 years of experience, has excelled in diverse markets and businesses, including medical technology, orthopedics, and consumer health. He oversees Shalby's implant business globally, guiding strategic endeavors. Previously, he held the position of Vice President - Orthopedics at DePuy Synthes, a division of J&J Medical Asia Pacific, and was a valued member of the J&J Global Orthopedic management team.



Mr. Shyamal Joshi Independent Director

Associated with Shalby Hospitals since 2010, Mr. Joshi holds a bachelor's degree in commerce from Gujarat University and is a member of the ICAI. He has huge working experience that spans corporate strategy, fund raising, acquisition, merger, taxation and accounting among others. Currently, he holds directorship of various other Companies.



Dr. Umesh Menon Independent Director

Dr. Menon has deep expertise in finance and cost accounting. He also holds MBA with specialization in Finance, and a fellow member of Institute of Cost Accountants of India. He has been conferred with the Doctorate (PhD) in Management. Currently, he also serves on the board of directors of various other companies. He is also an international expert and trainer for the United Nations Industrial Development Organization.



Mr. Vijay Kedia Independent Director

Mr. Vijay Kedia joined Shalby as an independent director on May 18, 2023. He is the Managing Director of Kedia Securities Pvt. Ltd. Holding directorships in companies such as Atul Limited and Greenline Tea & Exports Ltd, Kedia received a Doctorate in Management Excellence in 2016. His accomplishments include the "SARVOTTAM SAMMAN" in 2020, the Shri Babasaheb Ambedkar Award, and the Shri Abdul Kalam Award. A well-known figure in the investment community, Kedia has inspired numerous young investors.

## **Shalby Awards and Accolades**







FICCI Medical Value Travel Specialist Award 2023 (Orthopedics & Joint Replacement) to Krishna Shalby Hospital



Shalby Orthopedics Centre of Excellence -SOCE Lucknow Wins Medical Excellence Award





Medgate Today Healthcare Award 2023 for Single Specialty of the Year in Orthopedics Category

## **Shalby In News**



## **Dengue, viral fever grip city**

'Hospitalization Rate Is About 15% Of OPDs'

Ahmedabad: Many citizens are suffering from high or low-grade fevers, cough, cold and bodyache: symptoms of viral conditions.

r vector-borne diseases. While the number of dengue cases had dipped when temperatures rose at the begin-ning of September, the fresh zing and washing hands frespell of light rain with lower quently" he said.

cians said 10% to 15% of all

Dr Rushikesh Shah, a physician with Zydus Hospital, let counts along with impact said the number of cases of on the liver and heart. While dengue has increased companumbers are not as high as the timing of the test is imporabout a month ago, but there tant, and one should not let were very few cases in early September, with flu cases be-symptoms abate," he said.

These days we are witnes- CEO of Jivraj Mehta H sing viral infections and denge" he said. "We can expect

Termed 'seven-day fever' ys," he said.

ents first experiencing a high ys along with cough and cold, ollowed by three to four days

Times News Network of body ache and weakness physician, said multiple viral infections are prevalent in the city with conducive weather

"The need of the hour is to break the infection chain with good personal hygiene, cove-

Dr Minesh Mehta, a criti-cal care specialist at Shalby Hospital, said the OPD to ho-

CHANGING WEATHER spitalization rate is about 10% to 15% in

lization due to dengue typicalcheck. Measure it regularly and if a ly report a rapid drop in platehigh-grade (around 102°F) there are dengue-like sympconsult a doctor

Dr Maneesh Agarwal, coconut water etc. said that for the past few days



influenza or the flu Dengue patients face rapid fall in platelet count and impact on heart Hospitalization lasts from two to 10 days. depending on symptoms. Patients are from all age groups, including children

consulting a doctor. Avoid Avoid spreading the virus. Make sure you cover your face while sneezing

Stay
hydrated. Drink
good amounts of
water, soup, juice,

#### they have been getting 15 to 20 City may see high temperatures, dry weather

dengue cases to continue till
Navratri. For viral fevers, pacases. "We are seeing cases

Ahmedabad: According to the India Meteorological Department
(IMD), the city can expect high temperatures and dry weather in tients need symptomatic tre- from almost all age groups, in- the coming days. While some parts of South Guiarat may atment. Typically, the symp-toms last for five to seven da-toms last for five to seven da-tation. The average hospitali-tation are five to seven da-tation. The average hospitali-tation are five to seven da-tation are five to seven da-tation. The average hospitali-tation are five to seven da-tation are five to seven da-tation. The average hospitali-tation are five to seven da-tation are five to seven da-tation. The average hospitali-tation are five to seven da-tation are five to seven da-tation. The average hospitali-tation are five to seven da-tation are five zation period is four to five da- later this month. On Monday, the maximum temperature reached 34.5 degrees celsius, which was 1.4 degrees above normal. TNN



According to the doctor, the underlying cause of behaviors. Parties and the properties of the properti

angioplasty were done through her right hand. It is



#### वर्ल्ड फिजियोथैरेपी डे: बदलती लाइफस्टाइल का असर दिखाई दे रहा युवा पीढ़ी पर तीन सालों में बढे फिजियोथैरेपी के मामले, 30 से 40% इजाफा



पीचार विकास कर हैंगे हों है में बार पा पा को के हुए के प्राप्त कर प्राप्त कर कि नहीं है कि प्राप्त कर कि प्राप्त

शहरों में स्थपित किए जारी । ताकि

सभी के लिए गणवलपूर्ण स्वास्थ्य सेवा

सुलभ हो सके । आगे बताया कि

अस्पताल में सपर स्पेत्रलिस्ट और

कंसलटेंट की टीम है जो उपक्र

चिकित्सा देखभाल सुरक्षित वातावरण

भी प्रदान करता है। आपने तीन

लिए हमारी पुरी सहायता का आश्वासन देते हैं।

शैल्बी मल्टी स्पेशियलिटी हॉस्पिटल इंदौर में हाल ही में ईको वर्कशॉप-2023 का आयोजन किया गया, जहां शैल्बी हॉस्पिटल के

से डॉक्टर्स की समझाया।

शैल्बी में हुई लाइव ईको वर्कशॉप र्डको कार्डियोग्राफी का दिया प्रशिक्षण

शैल्बी हॉस्पिटल के परिवार से जुड़े न्यूरोसर्जन

डॉ मलचंदानी के पास एमबीबीएस, एम एस एवं दिल्ली से न्यरोसर्जरी में

डीएनबी जैसी योग्यताएं है। वे स्पाइन सर्जरी, न्यूरोनकोलॉजी. न्यरोटॉमा. बाल

चिकित्सा न्यरोसर्जरी और वैस्कलर न्यरोसर्जरी जैसी विधाओं में दक्ष हैं एवं

एंडोस्कोपिक स्पाइन सर्जरी (युबीई और ट्रांसफोरामिनल एंडोस्कोपी) में

विशेष रूप से प्रशिक्षित है, जिसका लाभ ब्रेन एवं स्पाइन से जुड़ी समस्याओं

से जुझ रहे मरीज शैल्बी हॉस्पिटल पहुंचकर ले सकते हैं। न्यूरोसर्जन डॉ

संदीप मुलचंदानी ने इस मौके पर कहा, मुझे बेहद खुशी है कि मैं शैल्बी

परिवार से जड़ रहा हूँ यहाँ वे सारी सुविधाएँ एवं उपकरण मौजूद हैं जिनसे हम मरीजों को बेहतर स्वास्थ्य सविधाएँ दे सकते हैं। शैल्बी हॉस्पिटल के

मेडिकल सप्रिटेंडेंट डॉ विवेक जोशी ने कहा शैल्बी परिवार डॉ मुलचंदानी का

अपने परिवार में हार्दिक स्वागत करता है, हम न्यूरोसर्जरी की सफलता के

डॉ संदीप मूलचंदानी

इंदौर, । मेडिकल हब के रूप

में स्थापित हो चके इंदौर में

मस्तिष्क की बीमारी से जड़े

रोगियों के लिए अच्छी खबर

है। मरीजों की बेहतर

न्यरोसर्जन डॉ संदीप

जुड गए हैं।

चिकित्सा, सुविधा के लिए

मुलचंदानी अब इंदौर के

शैल्बी हॉस्पिटल परिवार से

मो.नं. 7879619664

कार्डियोलॉजिस्टों ने इंदौर और इंदौर के आसपास के क्षेत्र के जनरल फिजिशियन को ईको कार्डियोग्राफी का प्रशिक्षण दिया और इसकी मदद से हार्ट के मरीजों के उत्नत इलाज की जानकारी दी। सबह 9 बजे से शुरू हुई इस वर्कशॉप का मुख्य आकर्षण 5 लाइव ईको लैब्स थे, कार्डियक साइंस के डायरेक्टर जहां एडवांस ईको मशीन पर

साथ साथ ही 9 बेसिक ईकी टॉक्स भी दिए गए. जिसमें ईंको कार्डियोग्राफी को बहुत ही सरलता

## शैल्बी हॉस्पिटल ने सेप्सिस पर जागरूकता फैलाने के लिए चलाया अभियान

इंदौर। हाल ही में शैल्बी मल्टीस्पेशलिटी हॉस्पिटल इंदौर ने सेप्सिस के प्रति लोगों को जागरूक करने के लिए अभियान चलाया, जिसमें शैल्बी का स्टाफ हाथ में 'क्विक एक्शन फॉर सेव लाइफ फ्रॉम सेप्सिस की तिख्तयों एवं बैनर के साथ नजर आए। इस अभियान का उद्देश्य सेप्सिस के बारे में **मरीजों और मेडिकल स्टाफ को जागरूक** बेहद गंभीर हो जाती है। इस स्थिति में ब्लड प्रेशर

जब गंभीर बीमारियों या मरीजों को प्रोटोकॉल के हिसाब से इलाज नहीं मिल पाता तो अकसर संक्रमण फैल जाता है। यह स्थिति है। डब्ल्यएचओ की रिपोर्ट के अनुसार विश्व में हुए तुरंत इंटेंसिविस्ट/फिजिशियन (इन्फेक्शन लोगों को जागरूक करते हुए कहा कि संक्रमण हैं, जिससे मरीज की जान भी जा सकती है।



सेप्सिस का रूप तब लेता है, जब इसकी स्थिति कम हो जाता है एवं शगर की मात्रा बढ़ जाती है। यहां एंटीवायरल, एंटीबॉयोटिक, एंटीफंगल एवं एंटीपैरासिटिक डग्स के साथ एक बेहतर देखभाल की भी जरूरत होती है, अन्यथा स्थिति सेप्सिस कहलाती है। वैसे तो सेप्सिस की चपेट बिगड सकती है। जागरूकता अभियान के में वे लोग आते हैं. जिनकी रोग प्रतिरोधक क्षमता माध्यम से मरीजों को भी यह समझना जरूरी है कमजोर होती है, लेकिन यह एक गंभीर समस्या कि इन्फेक्शन होने पर उसे नजरअंदाज न करते होने वाली मौतों के पांच प्रमख कारणों में से एक का उपचार करने वाले डॉक्टर) से संपर्क करें सेप्सिस भी है। शैल्बी हॉस्पिटल के मेडिकल गोल्डन ऑवर्स में इसका उपचार होना जरूरी है सपरिटेंडेंट डॉ. विवेक जोशी ने सेप्सिस पर देर होने पर मल्टीपल ऑर्गन फैलियर हो सकते



इंदौर 🗯 राज न्यूज नेटवर्क

मुंबई के होटल ताज पैलेस में 1 सितम्बर को सेफ इंडिया हीरो प्लस अवार्ड समारोह का आयोजन किया गया। इस समारोह में इंदौर के शैल्बी हॉस्पिटल के सीनियर फायर सेफ्टी ऑफिसर शंकर पुरी गोस्वामी को बेस्ट फायर फाइटर एवं बेस्ट सेफ्टी प्रोफेशनल अवार्ड से सम्मानित किया गया। अवार्ड समारोह में मख्य अतिथि के रूप में महाराष्ट्र के श्रम मंत्री सरेश खाडे और मुंबई के मुख्य अग्निशमन अधिकारी संतोष वारिक निदेशक महाराष्ट्र अग्निशमन सेवा और सीएफओ एमआईडीसी मौजूद रहे, जिन्होंने विजेताओं को सम्मानित किया।

शैल्बी हॉस्पिटल के मेडिकल सुपरिटेंडेंट डॉ विवेक जोशी ने इस अवसर पर कहा कि शैल्बी



हॉस्पिटल चिकित्सा सुविधाओं के अलावा भी हॉस्पिटल में सारी सावधानियां बरतता है. जिसके लिए हमारे पास एक दक्ष टीम मौजद है। हमें गर्व है कि शैल्बी के फायर फाइटर को ये सम्मान मिला, हम अवार्ड पाने वाले सीनियर फायर सेफटी ऑफिसर शंकर को पूरे शैल्बी परिवार की ओर शभकामनाएं देते हैं।

दुनिया का सबसे बड़ा ज्वाइंट रिप्लेसमेंट सेंटर वाला अस्पताल अब रांची में रांची : अहमदाबाद, सूरत , जवपुर , एक है और पूर्वी भारत में यह इसका

लावनर हेंगे जबलपा खालिया पहल अम्पनल है। गंबी के ह्या उदयपर सरित अब रांची रेलवे स्टेशन अस्पताल की धमता 70 बेडों की है। और ओकब्रिज के बस डिपो के मख्य रूप से इलाज : रमेटोलॉर्ज नजदीक सिरम दोली स्थित दनिया का ऑबोपिडिक्स .क्वाइंट रिप्लेसमेंट सबसे बड ज्वाइंट रिप्लेसमेंट सेंटर के हेमेटोलॉजी, किडनी रेग, युरेलॉजी रूप में चर्चित क्रेन्ब्री मल्टीस्पेक्सिटी न्योलॉजी क्रिटिकल केया हॉस्पिटल का सेल्फी डिवाइन सपर कार्डियोलॉजी आदि सहित करीब 15 किया गया है। अस्पातान का उद्धारन व्यवस्थित की गई है।

शैल्बी पश्चिमी और मध्य भारत के लिमिटेड के सीएमडी और विश्व प्रसिद्ध के साथ अस्पतालों की स्थापना के अस्पताल स्थापत करने की योजना हैं।

संप्रतिस्ट हॉस्पिटल के सांबंदियों में से अधिक संप्रतिनदी के उपचार एवं ज्वाइंट रिलेसमेंट सर्जन डॉक्टर विक्रम माध्यम से हमारा उद्देश उत्तर स्वास्थ्य विष्टें के माध्यम से संक्रमण को 15 वां अस्पताल रांची में शुभारंभ आधनिक सविधाओं के साथ शहर ने बताय कि वर्तमान में छोटे शहरों देखभाल और रेगी देखभाल के बीच जोखिम को निर्वादत करता है। समर

में बढ़ी संख्या में लोगों को गणवतापर्ण अंतर को कम करना है। जो हमेजा स्पेजलिटी हॉस्पिटल के डावरेक्टर डा रील्बी के अध्यक्ष एवं प्रबंध निदेशक **ज्वाइंट स्थिनमेंट सर्जन डॉक्टर** इलाज के लिए काफी दूरी तय करके हमारी ताकत रही है तीन-चार वर्षों से देवनीश खेस ने कहा कि सैत्बी सीएमडी डॉ विक्रम शह ने किया। विक्रम शाह ने बताया: कैन्बी बडे शहरों में जान पड़ता है। इस सोच परे भारत में बडें और कररी-सोशलिटी डॉस्पिटल के साथ जड़कर बहुत ख़ज़

वर्कशॉप के ऑर्गनाइजर शैल्बी हॉस्पिटल के इंस्टिट्यूट ऑफ कार्डियोलॉजिस्ट डॉ. सिद्धांत जैन ने प्रशिक्षित कार्डियोलॉजिस्ट की टीम इंको कार्डियोग्राफी द्वारा किए जा रहे का पता लगाया जा सकता है और द्वारा जनरल फिजिशियन को हैंड आधुनिक इलाज की जानकारी देते समय पर उपचार मिलने से लंबे ऑन प्रैक्टिस करवाई गई। इसके हुए कहा मौजूदा समय में ईको समय में फायदा मिल सकता है।



## **DISCLAIMER and CONTACT DETAILS**

No representation or warranty, express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of its date. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements", including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects, and future developments in its industry and its competitive and regulatory environment. Actual results may differ materially from these forward-looking statements due to a number of factors, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions in India. This communication is for general information purpose only, without regard to specific objectives, financial situations and needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any shares in the Company and neither any part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes. This presentation cannot be copied and/or disseminated in any manner.

### For further information, please contact:

Puneet Maheshwari AGM, Investor Relations & Corp. Strategy

+91 9512049871 ircs3.corp@shalby.org

SHALBY LIMITED I Regd Off: Opp. Karnavati Club, S.G. Road, Ahmedabad – 380015, Gujarat, India. Phone: 079 4020 3000 Fax: +91 79 4020 3109 |

Website: www.shalby.org | CIN: L85110GJ2004PLC044667